“Eszopiclone and lemborexant work for insomnia despite adverse events, while prescription drugs such as benzodiazepines, daridorexant, suvorexant, and trazodone can be effective but are associated with poor tolerability, according to this systematic review and meta-analysis.”

Scientists have started questioning the veracity of images accompanying University of Minnesota Sylvain Lesné, PhD’s studies touting major breakthroughs. Lesné’s images had supported a theory that oligomer species Aβ*56 was the most important of many oligomers thought to be more pathogenic than other plaques — and thus, a potential drug target.

Dr. Janos Tanyi, Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania, is joined by Dr. Charles Turck to discuss fluorescence-guided, intraoperative imaging as well as a new imaging drug to help physicians better detect ovarian cancer.

This phase III trial evaluated the PARP inhibitor fuzuloparib versus placebo as a maintenance treatment after second- or later-line platinum-based chemotherapy in patients with high-grade, platinum-sensitive, recurrent ovarian cancer. Two-hundred-fifty-two (252) patients were randomly assigned to the fuzuloparib (n = 167) or placebo (n = 85). Twice daily oral fuzuloparib as maintenance therapy was superior to placebo in PFS improvement. Further, benefit was observed both in patients with germline BRCA 1/2 mutations and in those without mutations.

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

In this study of neoadjuvant chemotherapy with ruxolitinib, approximately 130 patients were randomized to receive dose-dense neoadjuvant chemotherapy with or without ruxolitinib, followed by interval debulking and finally three more cycles of dose-dense neoadjuvant chemotherapy with or without ruxolitinib. The ruxolitinib group experienced a 3-month difference in progression-free survival.